Estimation of patients affected by inflammatory bowel disease potentially eligible for biological treatment in a real-world setting
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2023.04.022 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Luca Degli Esposti und 8 weiteren Autor:innen. Beteiligte Einrichtung: CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, Italy. Electronic address: luca.degliesposti@clicon.it. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND/AIMS: This analysis estimated the number of inflammatory bowel disease (IBD) patients presenting criteria of eligibility for biological therapies in an Italian real-world setting. METHODS: An observational analysis was performed on administrative databases of a sample of Local Health Units, covering 11.3% of the national population. Adult IBD patients (CD or UC) from 2010 to the end of data availability were included. Eligibility criteria for biologics were the following: Criterion A, steroid-refractory active disease; Criterion B, steroid-dependent patients; Criterion C, intolerance or contraindication to conventional therapies; Criterion D, severe relapsing disease; Criterion E (CD only), highly active CD disease and poor prognosis. RESULTS: Of 26,781 IBD patient identified, 18,264 (68.2%) were treated: 3,125 (11.7%) with biologics and 15,139 (56.5%) non-biotreated. Among non-biotreated, 7,651 (28.6%) met at least one eligibility criterion for biologics, with criterion B (steroid-dependence) and criterion D (relapse) as the most represented (58-27% and 56-76%, respectively). Data reportioned to the Italian population estimated 67,635 patients as potentially eligible for biologics. CONCLUSIONS: This real-world analysis showed a trend towards undertreatment with biologics in IBD patients with 28.6% being potentially eligible, suggesting that an unmet medical need still exists among the Italian general clinical practice for IBD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, Italy. Electronic address: luca.degliesposti@clicon.it.
- CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, Italy.
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, Milan, Italy.
- IBD Unit, DIMEC, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
- Gastroeterology Unit, Mauriziano Hospital, Turin, Italy.
- IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Zitieren
APA
Degli Esposti, L., Perrone, V., Sangiorgi, D., Saragoni, S., Dovizio, M., Caprioli, F., Rizzello, F., Daperno, M., & Armuzzi, A. (2024). Estimation of patients affected by inflammatory bowel disease potentially eligible for biological treatment in a real-world setting. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.04.022
Vancouver
Degli Esposti L, Perrone V, Sangiorgi D, Saragoni S, Dovizio M, Caprioli F, et al. Estimation of patients affected by inflammatory bowel disease potentially eligible for biological treatment in a real-world setting. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.04.022
BibTeX
@article{DegliEsposti2024,
author = {Degli Esposti, Luca and Perrone, Valentina and Sangiorgi, Diego and Saragoni, Stefania and Dovizio, Melania and Caprioli, Flavio and Rizzello, Fernando and Daperno, Marco and Armuzzi, Alessandro},
title = {Estimation of patients affected by inflammatory bowel disease potentially eligible for biological treatment in a real-world setting},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2023.04.022}
}
EUVIMED